‘Sell America’ trade back in the headlines, with various reports highlighting nearly US$5tn in value erased from the S&P 500 ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Novo Nordisk now has an Ozempic pill. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...

"With these costs trending so nicely downward, just what I predicted they would do, there can almost be no inflation, but ...

Novo Nordisk (NYSE:NVO) shares sank more than 7% in Copenhagen after Eli Lilly (NYSE:LLY) released promising trial results for its experimental obesity pill, orforglipron, which showed weight loss and ...

After some tough weeks, the Danish stock market opened poorly following the Easter holidays. The C25 index fell by 1.7% in ...

The scale of President Donald Trump’s tariffs has exceeded even the most bearish forecasts — and could impact these five ...

We recently published a list of Top 20 Falling Stocks with Unusual Volume. In this article, we are going to take a look at ...

Eli Lilly's robust sales for Mounjaro and Zepbound along with its positive outlook for 2025 also work in its favor. Click ...